世界のアクティブアプロクシメータ血管閉鎖デバイス（VCD）市場 – 2029年までの業界動向と予測

Get Exclusive Sample PDF of this Report Here

アクティブアプロクシメータ血管閉鎖デバイス（VCD）市場分析と規模

WHOのデータによると、心血管疾患による死亡の5分の4以上は脳卒中と心臓発作によるもので、これらの死亡の3分の1は70歳未満で起こると考えられています。欧州心臓病学会（ESC）（2021年）は、心血管疾患（CVD）により、欧州では年間390万人、欧州連合では180万人以上が亡くなっていると報告しています。これらは、欧州全体の死亡の約45％、欧州連合内の死亡の37％を占めています。

Data Bridge Market Researchは、2021年に8億770万米ドルであったアクティブアプロクシメータ血管閉鎖デバイス（VCD）市場は、2029年までに14億5127万米ドルに急増し、2022年から2029年の予測期間中に7.60％のCAGRを達成すると分析しています。市場価値、成長率、市場セグメント、地理的範囲、市場プレーヤー、市場シナリオなどの市場洞察に加えて、Data Bridge Market Researchチームがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

アクティブアプロクシメータ血管閉鎖デバイス（VCD）市場の範囲とセグメンテーション     

Get Exclusive Sample PDF of this Report Here

市場の定義

血管造影後、コラーゲンまたは縫合糸片が血管閉鎖装置として使用されます。血管閉鎖装置は、血管造影で動脈穿刺が残る場合に有効です。穿刺された動脈は血管閉鎖装置を使用して密閉されます。患者の身体は血管閉鎖装置によって悪影響を受けません。

アクティブアプロクシメータ血管閉鎖デバイス（VCD）市場の動向

ドライバー

• 心血管疾患の有病率が高い

全世界で、心血管疾患 (CVD) は主な死亡原因の 1 つとなっています。米国心臓協会 (AHA) は、2019 年に CVD が原因で 1,860 万人が死亡したと推定しており、これらの死亡の大部分は東ヨーロッパと中央アジアで発生しています。AHA の予測によると、2030 年までに米国の人口の 40.5% が CVD を患うことになります。したがって、CVD の有病率が上昇するにつれて、CVD の診断と治療のためのカテーテル挿入と介入治療の需要が高まると予測されています。今後数年間、これらの治療法の人気の高まりにより、アクティブ アプロクシメータ血管閉鎖装置の市場は大幅に成長すると予測されています。

• 血管閉鎖デバイスの承認と消費者の傾向の増加

アクティブアプロクシメータ血管閉鎖装置市場の成長を牽引する主な要因は、人口における心血管疾患の罹患率の上昇です。市場の成長に影響を与えるその他の間接的な要因としては、消費者の可処分所得の増加や、大口径血管閉鎖装置に対する企業の関心の高まりなどがあります。血管閉鎖装置の承認の増加や、低侵襲処置に対する消費者の傾向は、市場拡大のより実りある機会を生み出すでしょう。肥満率の上昇も、市場拡大の基盤を整えるでしょう。

機会

• 病院と外科センターの数の増加

The growing patient population is a considerable need for surgical supplies (including medical equipment like vascular closure devices) at these recently opened surgical centres and hospitals. As the primary end users of vascular closure devices, the significant increase in hospitals and surgical facilities is anticipated to drive the growth of the active approximators vascular closure devices market.

Restraints/Challenges

• High cost of vascular closure devices

When compared to manual compression devices, vascular closure devices are more expensive. Vascular closure devices typically cost between $150 and $250, whereas manual compression devices cost between $15 and $25. VCD expenses essentially add to the patient's hospital bill, raise hospitals' per-patient expenses, and at the same time lower their earnings. On the other hand, manual compression devices have very cheap prices when compared to vascular closure devices. As a result, one of the main factors restricting the market's growth is the high price of vascular closure devices. Another significant barrier limiting the market for these devices is the fact that hospitals are not compensated for vascular closure devices.

This active approximators vascular closure device (VCDs) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the active approximators vascular closure device (VCDs) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Active Approximators Vascular Closure Device (VCDs) Market

The COVID-19 outbreak's statewide lockdowns, refusal of wound care services, and cancellation or postponement of elective procedures, the market for active approximators vascular closure devices suffered in 2020. In order to reserve or reallocate the limited capacities and resources (such hospital beds and patient care specialists) toward COVID-19 patient care, elective procedures were being refused (cancelled/postponed). Additionally, many nations had implemented curfews and lockdowns to reduce the rising number of COVID-19 instances. Patients were unable to visit clinics, hospitals, or OPDs as a result of these lockdowns. The expansion of the market for active approximators vascular closure devices is anticipated to be constrained by this temporary denial of non-emergent healthcare services. However, it is anticipated that demand for active approximator vascular closure devices would increase in the upcoming years.

Recent Development

• In July 2021, the new investigational product that is currently being developed, PerQseal Blue, was announced by Vivasure Medical. In particular, PerQseal Blue is made to be utilised in percutaneous cardiovascular procedures like transcatheter mitral valve repair or replacement (TMVR) and transcatheter tricuspid valve repair or replacement for suture-less, fully absorbable large-bore venous artery closure (TTVR).
• In March 2021, the main CE Mark study for CyndRx LLC's AbsorbaSealTM vascular closure device, which was designed to assess the safety and effectiveness of this polymer-based device, was completed with strong clinical results.
• In January 2021, Haemonetics Corporation and Cardiva Medical Inc., a privately held producer of vascular closure systems, signed a legally binding agreement to combine their businesses.

Global Active Approximators Vascular Closure Device (VCDs) Market Scope

The active approximators vascular closure device (VCDs) market is segmented on the basis of type, access, procedure, distribution channel, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Passive Approximators
• Collagen Plugs
• Sealant or Gel-based Devices
• Compression Assist Devices
• Active Approximators
• Suture-based Devices
• Clip-based Devices
• External Hemostatic Devices

Access

• Femoral Access
• Radial Access

Procedure

• Interventional Cardiology
• Interventional Radiology/Vascular Surgery

Distribution Channel

• Direct Tenders
•  Retail

 Application

• Diagnostic Intervention
• Therapeutic Intervention

 End User

• Hospitals
• Clinics
• Specialty Centres
• Ambulatory Surgery Centres
• Others

Active Approximators Vascular Closure Device (VCDs) Market Regional Analysis/Insights

The active approximators vascular closure device (VCDs) market is analysed and market size insights and trends are provided by country, type, access, procedure, distribution channel, application, and end user as referenced above.

The countries covered in the active approximators vascular closure device (VCDs) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominated the global active approximators vascular closure devices market, due to the increasing prevalence of cardiovascular diseases.

Asia-Pacific is expected to witness the fastest growth in the next 7 years due to the emerging economies of China and India.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure growth Installed base and New Technology Penetration

The Global active approximators vascular closure device (VCDs) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Global active approximators vascular closure device (VCDs) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Global active approximators vascular closure device (VCDs) market. The data is available for historic period 2010-2020.

Competitive Landscape and Active Approximators Vascular Closure Device (VCDs) Market Share Analysis

アクティブ アプロクシメータ血管閉鎖装置 (VCD) 市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、アクティブ アプロクシメータ血管閉鎖装置 (VCD) 市場に関連する会社の焦点にのみ関連しています。

アクティブアプロクシメータ血管閉鎖装置 (VCD) 市場で活動している主要企業は次のとおりです。

• テルモ株式会社（日本）
• アボット（米国）
• カーディナルヘルス（米国）
• カーディバメディカル社（米国）
• メドトロニック（アイルランド）
• モリス・イノベーティブ（米国）
• テレフレックス株式会社（米国）
• メリットメディカルシステムズ（米国）
• Vasorum Ltd. (アイルランド)
• TZメディカル（米国）
• Vivasure Medical Ltd.（アイルランド）
• トリコル・バイオメディカル（米国）
• サイオンバイオメディカル（米国）
• アドバンスト ヴァスキュラー ダイナミクス (米国)
• マリンポリマーテクノロジーズ社（米国）
• トランスルミナルテクノロジーズ（米国）

SKU-68879